APO RESEARCH · REPORT
Alzheimer's Disease Drug
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
Product & engineering
Understand the product.
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
Selected research
Market Structure
Global Alzheimer's Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
The major players in global Alzheimer’s Disease Drug market include Allergan, Eisai, Novartis, Daiichi Sankyo, Merz Pharma, Pfizer, Johnson & Johnson, Lundbeck, etc. The top 3 players hold over 60% of global shares. Europe and North America are main markets, they occupy over 70% of the global market. Memantine and Donepezil are the main types, with a share about 70%. Early to Moderate Stages is the key application, which covers over 55% shares.
This report provides an overview of the global Alzheimer's Disease Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Alzheimer's Disease Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Alzheimer's Disease Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Alzheimer's Disease Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Alzheimer's Disease Drug Segment by Company
Allergan
Eisai
Novartis
Daiichi Sankyo
Merz Pharma
Pfizer
Johnson & Johnson
Lundbeck
Alzheimer's Disease Drug Segment by Type
Donepezil
Memantine
Rivastigmine
Others
Alzheimer's Disease Drug Segment by Application
Early to Moderate Stages
Moderate to Severe Stages
Alzheimer's Disease Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alzheimer's Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alzheimer's Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alzheimer's Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Alzheimer's Disease Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alzheimer's Disease Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Alzheimer's Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Alzheimer's Disease Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Donepezil
- Memantine
- Rivastigmine
- Others
Applications
- Early to Moderate Stages
- Moderate to Severe Stages
Companies covered
- Allergan
- Eisai
- Novartis
- Daiichi Sankyo
- Merz Pharma
- Pfizer
- Johnson & Johnson
- Lundbeck
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Alzheimer's Disease Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Alzheimer's Disease Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Alzheimer's Disease Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Alzheimer's Disease Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Alzheimer's Disease Drug Market Dynamics
- 2.1 Alzheimer's Disease Drug Industry Trends
- 2.2 Alzheimer's Disease Drug Industry Drivers
- 2.3 Alzheimer's Disease Drug Industry Opportunities and Challenges
- 2.4 Alzheimer's Disease Drug Industry Restraints
3 Alzheimer's Disease Drug Market by Manufacturers
- 3.1 Global Alzheimer's Disease Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Alzheimer's Disease Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Alzheimer's Disease Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Alzheimer's Disease Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Alzheimer's Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Alzheimer's Disease Drug Manufacturers, Product Type & Application
- 3.7 Global Alzheimer's Disease Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Alzheimer's Disease Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Alzheimer's Disease Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Alzheimer's Disease Drug Tier 1, Tier 2, and Tier 3
4 Alzheimer's Disease Drug Market by Type
- 4.1 Alzheimer's Disease Drug Type Introduction
- 4.1.1 Donepezil
- 4.1.2 Memantine
- 4.1.3 Rivastigmine
- 4.1.4 Others
- 4.2 Global Alzheimer's Disease Drug Sales by Type
- 4.2.1 Global Alzheimer's Disease Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Alzheimer's Disease Drug Sales by Type (2021-2032)
- 4.2.3 Global Alzheimer's Disease Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Alzheimer's Disease Drug Revenue by Type
- 4.3.1 Global Alzheimer's Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Alzheimer's Disease Drug Revenue by Type (2021-2032)
- 4.3.3 Global Alzheimer's Disease Drug Revenue Market Share by Type (2021-2032)
5 Alzheimer's Disease Drug Market by Application
- 5.1 Alzheimer's Disease Drug Application Introduction
- 5.1.1 Early to Moderate Stages
- 5.1.2 Moderate to Severe Stages
- 5.2 Global Alzheimer's Disease Drug Sales by Application
- 5.2.1 Global Alzheimer's Disease Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Alzheimer's Disease Drug Sales by Application (2021-2032)
- 5.2.3 Global Alzheimer's Disease Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Alzheimer's Disease Drug Revenue by Application
- 5.3.1 Global Alzheimer's Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Alzheimer's Disease Drug Revenue by Application (2021-2032)
- 5.3.3 Global Alzheimer's Disease Drug Revenue Market Share by Application (2021-2032)
6 Global Alzheimer's Disease Drug Sales by Region
- 6.1 Global Alzheimer's Disease Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Alzheimer's Disease Drug Sales by Region (2021-2032)
- 6.2.1 Global Alzheimer's Disease Drug Sales by Region (2021-2026)
- 6.2.2 Global Alzheimer's Disease Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Alzheimer's Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Alzheimer's Disease Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Alzheimer's Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Alzheimer's Disease Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Alzheimer's Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Alzheimer's Disease Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Alzheimer's Disease Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Alzheimer's Disease Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Alzheimer's Disease Drug Revenue by Region
- 7.1 Global Alzheimer's Disease Drug Revenue by Region
- 7.1.1 Global Alzheimer's Disease Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Alzheimer's Disease Drug Revenue by Region (2021-2026)
- 7.1.3 Global Alzheimer's Disease Drug Revenue by Region (2027-2032)
- 7.1.4 Global Alzheimer's Disease Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Alzheimer's Disease Drug Revenue (2021-2032)
- 7.2.2 North America Alzheimer's Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Alzheimer's Disease Drug Revenue (2021-2032)
- 7.3.2 Europe Alzheimer's Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Alzheimer's Disease Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Alzheimer's Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Alzheimer's Disease Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Alzheimer's Disease Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Allergan
- 8.1.1 Allergan Company Information
- 8.1.2 Allergan Business Overview
- 8.1.3 Allergan Alzheimer's Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Allergan Alzheimer's Disease Drug Product Portfolio
- 8.1.5 Allergan Recent Developments
- 8.2 Eisai
- 8.2.1 Eisai Company Information
- 8.2.2 Eisai Business Overview
- 8.2.3 Eisai Alzheimer's Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Eisai Alzheimer's Disease Drug Product Portfolio
- 8.2.5 Eisai Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Company Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis Alzheimer's Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Novartis Alzheimer's Disease Drug Product Portfolio
- 8.3.5 Novartis Recent Developments
- 8.4 Daiichi Sankyo
- 8.4.1 Daiichi Sankyo Company Information
- 8.4.2 Daiichi Sankyo Business Overview
- 8.4.3 Daiichi Sankyo Alzheimer's Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Daiichi Sankyo Alzheimer's Disease Drug Product Portfolio
- 8.4.5 Daiichi Sankyo Recent Developments
- 8.5 Merz Pharma
- 8.5.1 Merz Pharma Company Information
- 8.5.2 Merz Pharma Business Overview
- 8.5.3 Merz Pharma Alzheimer's Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Merz Pharma Alzheimer's Disease Drug Product Portfolio
- 8.5.5 Merz Pharma Recent Developments
- 8.6 Pfizer
- 8.6.1 Pfizer Company Information
- 8.6.2 Pfizer Business Overview
- 8.6.3 Pfizer Alzheimer's Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Pfizer Alzheimer's Disease Drug Product Portfolio
- 8.6.5 Pfizer Recent Developments
- 8.7 Johnson & Johnson
- 8.7.1 Johnson & Johnson Company Information
- 8.7.2 Johnson & Johnson Business Overview
- 8.7.3 Johnson & Johnson Alzheimer's Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Johnson & Johnson Alzheimer's Disease Drug Product Portfolio
- 8.7.5 Johnson & Johnson Recent Developments
- 8.8 Lundbeck
- 8.8.1 Lundbeck Company Information
- 8.8.2 Lundbeck Business Overview
- 8.8.3 Lundbeck Alzheimer's Disease Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Lundbeck Alzheimer's Disease Drug Product Portfolio
- 8.8.5 Lundbeck Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Alzheimer's Disease Drug Value Chain Analysis
- 9.1.1 Alzheimer's Disease Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Alzheimer's Disease Drug Production Mode & Process
- 9.2 Alzheimer's Disease Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Alzheimer's Disease Drug Distributors
- 9.2.3 Alzheimer's Disease Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst